The U.S. Food and Drug Administration (USFDA) has approved a Biologics License Application (BLA) for a proposed biosimilar for Orencia (abatacept). The company’s 351(k) Biologics License Application (BLA) IV for infusion formulation for DRL-AB, for the proposed interchangeable biosimilar, was submitted in December 2025. “We are proud to be the first to submit a BLA […]
